8-K Announcements
6May 5, 2026·SEC
May 4, 2026·SEC
Feb 11, 2026·SEC
Inspire Medical Systems, Inc. (INSP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Inspire Medical Systems, Inc. (INSP) stock price & volume — 10-year historical chart
Inspire Medical Systems, Inc. (INSP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Inspire Medical Systems, Inc. (INSP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.10vs $0.28+136.3% | $205Mvs $200M+2.3% |
| Q1 2026 | Feb 11, 2026 | $1.65vs $0.69+139.1% | $269Mvs $266M+1.3% |
| Q4 2025 | Nov 3, 2025 | $0.38vs $0.15+353.3% | $225Mvs $262M-14.4% |
| Q3 2025 | Aug 4, 2025 | $0.45vs $0.22+104.5% | $217Mvs $214M+1.2% |
Inspire Medical Systems, Inc. (INSP) competitors in Respiratory and sleep therapy devices — business model, growth, and fundamentals comparison
Inspire Medical Systems, Inc. (INSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Inspire Medical Systems, Inc. (INSP) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 28.57M | 50.59M | 82.05M | 115.38M | 233.39M | 407.86M | 624.8M | 802.8M | 911.98M | 915.25M |
| Revenue Growth % | 73.9% | 77.1% | 62.18% | 40.62% | 102.28% | 74.75% | 53.19% | 28.49% | 13.6% | 8.94% |
| Cost of Goods Sold | 6.02M | 10.06M | 13.64M | 17.62M | 33.28M | 66.11M | 96.58M | 122.99M | 133.22M | 130.19M |
| COGS % of Revenue | 21.07% | 19.88% | 16.63% | 15.27% | 14.26% | 16.21% | 15.46% | 15.32% | 14.61% | - |
| Gross Profit | 22.55M▲ 0% | 40.54M▲ 79.8% | 68.41M▲ 68.8% | 97.76M▲ 42.9% | 200.12M▲ 104.7% | 341.74M▲ 70.8% | 528.22M▲ 54.6% | 679.82M▲ 28.7% | 778.76M▲ 14.6% | 785.06M▲ 0% |
| Gross Margin % | 78.93% | 80.12% | 83.37% | 84.73% | 85.74% | 83.79% | 84.54% | 84.68% | 85.39% | 85.78% |
| Gross Profit Growth % | 80.08% | 79.77% | 68.75% | 42.91% | 104.7% | 70.77% | 54.57% | 28.7% | 14.55% | - |
| Operating Expenses | 38.55M | 60.91M | 103.3M | 153.97M | 239.97M | 389.33M | 568.49M | 643.74M | 727.8M | 733.74M |
| OpEx % of Revenue | 134.95% | 120.4% | 125.9% | 133.44% | 102.82% | 95.46% | 90.99% | 80.19% | 79.8% | - |
| Selling, General & Admin | 32.36M | 53.53M | 90.47M | 127.87M | 202.62M | 320.69M | 451.96M | 529.61M | 624.64M | 632.55M |
| SG&A % of Revenue | 113.27% | 105.8% | 110.26% | 110.83% | 86.81% | 78.63% | 72.34% | 65.97% | 68.49% | - |
| Research & Development | 6.19M | 7.39M | 12.84M | 26.09M | 37.35M | 68.64M | 116.54M | 114.13M | 103.17M | 101.19M |
| R&D % of Revenue | 21.68% | 14.6% | 15.65% | 22.61% | 16% | 16.83% | 18.65% | 14.22% | 11.31% | - |
| Other Operating Expenses | 42K | -16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16M▲ 0% | -20.38M▼ 27.3% | -34.9M▼ 71.2% | -56.21M▼ 61.1% | -39.85M▲ 29.1% | -47.59M▼ 19.4% | -40.27M▲ 15.4% | 36.08M▲ 189.6% | 50.95M▲ 41.2% | 51.32M▲ 0% |
| Operating Margin % | -56.02% | -40.28% | -42.53% | -48.72% | -17.07% | -11.67% | -6.45% | 4.49% | 5.59% | 5.61% |
| Operating Income Growth % | 7.25% | -27.34% | -71.25% | -61.07% | 29.1% | -19.43% | 15.38% | 189.6% | 41.21% | - |
| EBITDA | -15.72M | -19.98M | -34.4M | -55.37M | -38.63M | -45.73M | -37.42M | 42.63M | 64.91M | 62.23M |
| EBITDA Margin % | -55.02% | -39.5% | -41.93% | -47.99% | -16.55% | -11.21% | -5.99% | 5.31% | 7.12% | 6.8% |
| EBITDA Growth % | 8.35% | -27.15% | -72.14% | -60.94% | 30.23% | -18.38% | 18.17% | 213.92% | 52.26% | 6.25% |
| D&A (Non-Cash Add-back) | 285K | 393K | 495K | 840K | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M | 10.91M |
| EBIT | -15.76M | -18.52M | -31.08M | -54.97M | -39.84M | -42.59M | -19.91M | 58.48M | 50.95M | 57.34M |
| Net Interest Income | -1.55M | -1.43M | 1.68M | -1.02M | -2M | 3.37M | 20.56M | 23.23M | 17.4M | 12.33M |
| Interest Income | 203K | 1.87M | 3.8M | 1.09M | 125K | 5.05M | 20.56M | 23.25M | 17.54M | 12.47M |
| Interest Expense | 1.75M | 3.3M | 2.12M | 2.12M | 2.13M | 1.68M | 0 | 22K | 137K | 137K |
| Other Income/Expense | -1.51M | -1.45M | 1.69M | -880K | -2.12M | 3.32M | 20.36M | 22.37M | 14.74M | 12.61M |
| Pretax Income | -17.51M▲ 0% | -21.83M▼ 24.7% | -33.2M▼ 52.1% | -57.09M▼ 71.9% | -41.97M▲ 26.5% | -44.27M▼ 5.5% | -19.91M▲ 55.0% | 58.45M▲ 393.6% | 65.7M▲ 12.4% | 63.94M▲ 0% |
| Pretax Margin % | -61.3% | -43.14% | -40.47% | -49.48% | -17.98% | -10.85% | -3.19% | 7.28% | 7.2% | 6.99% |
| Income Tax | 0 | 0 | 40K | 115K | 72K | 613K | 1.25M | 4.94M | -79.72M | -67.2M |
| Effective Tax Rate % | 0% | 0% | -0.12% | -0.2% | -0.17% | -1.38% | -6.26% | 8.46% | -121.35% | -105.11% |
| Net Income | -17.51M▲ 0% | -21.83M▼ 24.7% | -33.24M▼ 52.3% | -57.2M▼ 72.1% | -42.04M▲ 26.5% | -44.88M▼ 6.8% | -21.15M▲ 52.9% | 53.51M▲ 353.0% | 145.42M▲ 171.8% | 131.14M▲ 0% |
| Net Margin % | -61.3% | -43.14% | -40.52% | -49.58% | -18.01% | -11% | -3.39% | 6.67% | 15.95% | 14.33% |
| Net Income Growth % | 5.49% | -24.65% | -52.3% | -72.08% | 26.5% | -6.75% | 52.87% | 352.96% | 171.77% | 97.18% |
| Net Income (Continuing) | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M | 145.42M | 131.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.30▲ 0% | -1.50▼ 15.4% | -1.40▲ 6.7% | -2.19▼ 56.4% | -1.54▲ 29.7% | -1.60▼ 3.9% | -0.72▲ 55.0% | 1.75▲ 343.1% | 4.89▲ 179.4% | 4.57▲ 0% |
| EPS Growth % | 12.75% | -15.38% | 6.67% | -56.43% | 29.68% | -3.9% | 55% | 343.06% | 179.43% | 107.04% |
| EPS (Basic) | -1.30 | -1.50 | -1.40 | -2.19 | -1.54 | -1.60 | -0.72 | 1.80 | 4.95 | - |
| Diluted Shares Outstanding | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 30.54M | 29.76M | 28.7M |
| Basic Shares Outstanding | 13.49M | 14.58M | 23.8M | 26.07M | 27.26M | 28.07M | 29.3M | 29.76M | 29.37M | 28.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Inspire Medical Systems, Inc. (INSP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.1M | 199.28M | 170.64M | 269.87M | 268.54M | 530.03M | 593.74M | 630.81M | 583.65M | 566.82M |
| Cash & Short-Term Investments | 16.14M | 188.21M | 149.47M | 234.36M | 214.47M | 451.41M | 460.38M | 445.55M | 308.27M | 98.93M |
| Cash Only | 8.96M | 97.29M | 22.86M | 190.52M | 214.47M | 441.59M | 185.54M | 150.15M | 104.81M | 98.93M |
| Short-Term Investments | 7.19M | 90.92M | 126.61M | 43.84M | 0 | 9.82M | 274.84M | 295.4M | 203.46M | 0 |
| Accounts Receivable | 3.86M | 6.67M | 13.13M | 25.06M | 34.18M | 61.23M | 89.88M | 93.07M | 119.69M | 105.09M |
| Days Sales Outstanding | 49.29 | 48.1 | 58.41 | 79.29 | 53.45 | 54.79 | 52.51 | 42.31 | 47.9 | 46.9 |
| Inventory | 3.67M | 2.67M | 5.83M | 8.48M | 17.23M | 11.89M | 33.88M | 80.12M | 145.29M | 166.24M |
| Days Inventory Outstanding | 222.59 | 96.8 | 156.08 | 175.61 | 188.99 | 65.62 | 128.07 | 237.78 | 398.06 | 402.98 |
| Other Current Assets | 426K | 1.73M | 0 | 0 | 0 | 5.5M | 9.6M | 12.07M | 10.4M | 196.56M |
| Total Non-Current Assets | 994K | 802K | 10.62M | 11.32M | 26.55M | 34.84M | 83.07M | 177.58M | 323.67M | 344.56M |
| Property, Plant & Equipment | 994K | 802K | 3.96M | 11.12M | 16.41M | 24.13M | 62.65M | 95.24M | 121.4M | 123.76M |
| Fixed Asset Turnover | 28.74x | 63.08x | 20.72x | 10.38x | 14.23x | 16.90x | 9.97x | 8.43x | 7.51x | 7.78x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 6.28M | 0 | 9.94M | 0 | 9.14M | 71M | 96.33M | 426.8M |
| Other Non-Current Assets | 0 | 0 | 381K | 204K | 204K | 10.71M | 11.28M | 11.34M | 6.09M | 44.79M |
| Total Assets | 25.09M▲ 0% | 200.08M▲ 697.4% | 181.25M▼ 9.4% | 281.19M▲ 55.1% | 295.08M▲ 4.9% | 564.88M▲ 91.4% | 676.81M▲ 19.8% | 808.38M▲ 19.4% | 907.32M▲ 12.2% | 911.38M▲ 0% |
| Asset Turnover | 1.14x | 0.25x | 0.45x | 0.41x | 0.79x | 0.72x | 0.92x | 0.99x | 1.01x | 1.06x |
| Asset Growth % | 91.3% | 697.42% | -9.41% | 55.14% | 4.94% | 91.43% | 19.82% | 19.44% | 12.24% | 49.91% |
| Total Current Liabilities | 7.15M | 11.15M | 16.86M | 20.73M | 41.31M | 61.19M | 78.11M | 88.5M | 96.06M | 89.42M |
| Accounts Payable | 3M | 3.43M | 4.46M | 7.21M | 11.66M | 26.85M | 38.84M | 38.69M | 36.56M | 41.85M |
| Days Payables Outstanding | 181.83 | 124.46 | 119.29 | 149.31 | 127.94 | 148.21 | 146.79 | 114.82 | 100.18 | 133.75 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 9.19M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 555K | 1.24M | 0 | 0 | 0 | 0 | 0 | 0 | 8.41M | 89.42M |
| Current Ratio | 3.37x | 17.86x | 10.12x | 13.02x | 6.50x | 8.66x | 7.60x | 7.13x | 6.08x | 6.08x |
| Quick Ratio | 2.86x | 17.63x | 9.78x | 12.61x | 6.08x | 8.47x | 7.17x | 6.22x | 4.56x | 4.56x |
| Cash Conversion Cycle | 90.05 | 20.44 | 95.2 | 105.59 | 114.5 | -27.8 | 33.79 | 165.27 | 345.79 | 316.14 |
| Total Non-Current Liabilities | 16.62M | 24.93M | 24.56M | 30.72M | 24.73M | 7.68M | 26.19M | 30.19M | 30.1M | 29.62M |
| Long-Term Debt | 16.46M | 24.93M | 24.52M | 24.75M | 15.8M | 7.54M | 0 | 0 | 0 | 29.55M |
| Capital Lease Obligations | 0 | 0 | 0 | 5.89M | 8.8M | 7.54M | 24.85M | 30.04M | 30M | 91.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.18M |
| Other Non-Current Liabilities | 157K | 0 | 40K | 85K | 134K | -7.39M | 1.35M | 148K | 104K | -29.61M |
| Total Liabilities | 23.61M | 36.08M | 41.42M | 51.44M | 66.04M | 68.87M | 104.3M | 118.69M | 126.16M | 119.04M |
| Total Debt | 16.46M | 24.93M | 25.35M | 30.63M | 34.09M | 16.41M | 24.85M | 31.79M | 32.16M | 29.55M |
| Net Debt | 7.5M | -72.36M | 2.49M | -159.89M | -180.37M | -425.18M | -160.69M | -118.36M | -72.66M | -69.38M |
| Debt / Equity | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.03x | 0.04x | 0.05x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.75x | 0.50x | 0.47x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -2.78x | -1.12x | -1.12x |
| Interest Coverage | -8.99x | -5.61x | -14.67x | -25.97x | -18.72x | -25.40x | - | 2657.95x | 371.93x | 418.58x |
| Total Equity | 1.48M▲ 0% | 164M▲ 10951.1% | 139.84M▼ 14.7% | 229.75M▲ 64.3% | 229.05M▼ 0.3% | 496.01M▲ 116.6% | 572.51M▲ 15.4% | 689.7M▲ 20.5% | 781.16M▲ 13.3% | 792.34M▲ 0% |
| Equity Growth % | 122.46% | 10951.15% | -14.73% | 64.3% | -0.3% | 116.55% | 15.42% | 20.47% | 13.26% | 39.8% |
| Book Value per Share | 0.11 | 11.25 | 5.87 | 8.81 | 8.40 | 17.67 | 19.54 | 22.58 | 26.25 | 27.61 |
| Total Shareholders' Equity | 1.48M | 164M | 139.84M | 229.75M | 229.05M | 496.01M | 572.51M | 689.7M | 781.16M | 792.34M |
| Common Stock | 13K | 23K | 24K | 27K | 27K | 29K | 30K | 30K | 29K | 29K |
| Retained Earnings | -125.08M | -146.91M | -180.16M | -237.35M | -279.39M | -324.27M | -345.42M | -291.91M | -146.49M | -157.79M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -52K | 102K | 29K | -55K | -86K | 800K | 536K | 464K | -352K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inspire Medical Systems, Inc. (INSP) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.79M | -18.69M | -33.38M | -53.05M | -20.12M | 11.57M | 24.65M | 130.25M | 116.98M | 116.98M |
| Operating CF Margin % | -55.28% | -36.95% | -40.68% | -45.97% | -8.62% | 2.84% | 3.95% | 16.22% | 12.83% | - |
| Operating CF Growth % | 12.02% | -18.38% | -78.54% | -58.93% | 62.07% | 157.5% | 113.1% | 428.32% | -10.19% | 3839.63% |
| Net Income | -17.51M | -21.83M | -33.24M | -57.2M | -42.04M | -44.88M | -21.15M | 53.51M | 145.42M | 131.14M |
| Depreciation & Amortization | 285K | 393K | 1.4M | 840K | 1.99M | 2.9M | 2.85M | 6.55M | 13.96M | 16.02M |
| Stock-Based Compensation | 243K | 1.22M | 0 | 12.82M | 0 | 0 | 82.47M | 116.01M | 0 | 129.93M |
| Deferred Taxes | 100K | -53K | 0 | -22K | 0 | 0 | 0 | 0 | -88.75M | 1.01M |
| Other Non-Cash Items | 315K | 714K | 5.04M | 1.4M | 26.79M | 51.74M | 1.27M | -7.51M | 133.73M | -97.59M |
| Working Capital Changes | 777K | 861K | -6.57M | -10.88M | -6.86M | 1.81M | -40.78M | -37.71M | -87.38M | -43.97M |
| Change in Receivables | -1.77M | -2.84M | -6.48M | -11.84M | -9.24M | -27.02M | -30.22M | -2.6M | -26.23M | -12.21M |
| Change in Inventory | -315K | 1M | -3.17M | -2.65M | -8.75M | 5.34M | -22M | -46.23M | -65.17M | -66.51M |
| Change in Payables | 1.82M | 439K | 1.03M | 2.05M | 4.78M | 14.36M | 9.3M | 604K | -3.75M | 12.9M |
| Cash from Investing | -7.6M | -83.39M | -43.56M | 86.63M | 29.14M | -19.6M | -294.82M | -113.12M | 21.45M | 11.75M |
| Capital Expenditures | -412K | -250K | -2.74M | -2.46M | -4.67M | -9.1M | -23.63M | -39.12M | -38.5M | -39.82M |
| CapEx % of Revenue | 1.44% | 0.49% | 3.34% | 2.13% | 2% | 2.23% | 3.78% | 4.87% | 4.22% | - |
| Acquisitions | 0 | 0 | 0 | -89.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -7.19M | -83.14M | 0 | 89.08M | 0 | -10.5M | 0 | 0 | 0 | 0 |
| Cash from Financing | 25.66M | 190.38M | 2.5M | 134.06M | 14.95M | 235.08M | 13.95M | -52.39M | -183.45M | -103.17M |
| Debt Issued (Net) | 458K | 8M | 0 | 0 | 0 | -24.5M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 25.2M | 182.38M | 2.5M | 134.06M | 14.95M | 259.62M | 31.11M | -47.23M | -160.41M | -91.84M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -75M | -175.02M | -100.01M |
| Other Financing | 0 | 0 | 0 | 0 | 0 | -43K | -17.16M | -5.17M | -23.04M | -11.33M |
| Net Change in Cash | 2.27M▲ 0% | 88.33M▲ 3791.3% | -74.43M▼ 184.3% | 167.66M▲ 325.3% | 23.95M▼ 85.7% | 227.13M▲ 848.4% | -256.06M▼ 212.7% | -35.39M▲ 86.2% | -45.34M▼ 28.1% | 45.05M▲ 0% |
| Free Cash Flow | -16.2M▲ 0% | -18.94M▼ 16.9% | -35.59M▼ 87.8% | -55.5M▼ 56.0% | -24.79M▲ 55.3% | 2.47M▲ 110.0% | 1.02M▼ 58.6% | 91.12M▲ 8798.7% | 78.48M▼ 13.9% | 96.71M▲ 0% |
| FCF Margin % | -56.72% | -37.44% | -43.37% | -48.1% | -10.62% | 0.61% | 0.16% | 11.35% | 8.61% | 10.57% |
| FCF Growth % | 11.24% | -16.92% | -87.84% | -55.96% | 55.34% | 109.98% | -58.59% | 8798.73% | -13.88% | 22.65% |
| FCF per Share | -1.20 | -1.30 | -1.49 | -2.13 | -0.91 | 0.09 | 0.03 | 2.98 | 2.64 | 2.64 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.86x | 1.00x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x | 0.80x | 0.74x |
| Interest Paid | 0 | 0 | 2.03M | 0 | 1.89M | 2.32M | 0 | 22K | 0 | 133K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inspire Medical Systems, Inc. (INSP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1179.99% | -26.38% | -21.88% | -30.96% | -18.33% | -12.38% | -3.96% | 8.48% | 19.77% | 17.98% |
| Return on Invested Capital (ROIC) | -210.81% | -30.38% | -22.37% | -39.73% | -50.43% | -59.74% | -12.52% | 5.51% | 5.97% | 5.97% |
| Gross Margin | 78.93% | 80.12% | 83.37% | 84.73% | 85.74% | 83.79% | 84.54% | 84.68% | 85.39% | 85.78% |
| Net Margin | -61.3% | -43.14% | -40.52% | -49.58% | -18.01% | -11% | -3.39% | 6.67% | 15.95% | 14.33% |
| Debt / Equity | 11.09x | 0.15x | 0.18x | 0.13x | 0.15x | 0.03x | 0.04x | 0.05x | 0.04x | 0.04x |
| Interest Coverage | -8.99x | -5.61x | -14.67x | -25.97x | -18.72x | -25.40x | - | 2657.95x | 371.93x | 418.58x |
| FCF Conversion | 0.90x | 0.86x | 1.00x | 0.93x | 0.48x | -0.26x | -1.17x | 2.43x | 0.80x | 0.74x |
| Revenue Growth | 73.9% | 77.1% | 62.18% | 40.62% | 102.28% | 74.75% | 53.19% | 28.49% | 13.6% | 8.94% |
Inspire Medical Systems, Inc. (INSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 4, 2026·SEC
Feb 11, 2026·SEC
Inspire Medical Systems, Inc. (INSP) stock FAQ — growth, dividends, profitability & financials explained
Inspire Medical Systems, Inc. (INSP) reported $915.2M in revenue for fiscal year 2025. This represents a 5472% increase from $16.4M in 2016.
Inspire Medical Systems, Inc. (INSP) grew revenue by 13.6% over the past year. This is steady growth.
Yes, Inspire Medical Systems, Inc. (INSP) is profitable, generating $131.1M in net income for fiscal year 2025 (15.9% net margin).
Inspire Medical Systems, Inc. (INSP) has a return on equity (ROE) of 19.8%. This is reasonable for most industries.
Inspire Medical Systems, Inc. (INSP) generated $96.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Inspire Medical Systems, Inc. (INSP) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates